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ABSTRACT 
Little is known about the correlates of comorbid drug and alcohol dependence in people with 
schizophrenia outside the USA. We tested hypotheses that dependence on alcohol or drugs would 
be associated with more severe symptoms, and poorer psychosocial functioning and quality of life. 
The EuroSC Cohort study (N=1,204), based in France, Germany and the UK, used semi-structured 
clinical interviews for diagnoses, and standardized tools to assess correlates. We used mixed models 
to compare outcomes between past-year comorbid dependence on alcohol or drugs, controlling for 
covariates and modelling both subject and country level effects. Participants dependent on alcohol 
or drugs had fewer negative symptoms on PANSS than their non-dependent counterparts. However, 
those dependent on alcohol scored higher on PANSS general psychopathology than those who were 
not dependent, or dependent only on drugs. People suffering from schizophrenia dependent on 
drugs had poorer quality of life, more extrapyramidal side effects, and scored worse on GAF than 
those without dependence. People with alcohol dependence reported more reasons for non-
compliance with medication, and poorer functioning on Global Assessment of Functioning (GAF), 
though not on Global Assessment of Relational Functioning (GARF). In people with schizophrenia, 
comorbid dependence on alcohol or drugs is associated with impaired clinical and psychosocial 
adjustment, and poorer quality of life. 
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1. Introduction 
A substantial proportion of people with schizophrenia misuse alcohol and other drugs (Green et al., 
2005; Swartz et al., 2006a; Koskinen et al., 2009; Koskinen et al., 2010), though this varies between 
different settings and geographical areas (Carrà et al., 2012). However, this body of research has 
been troubled by methodological issues. Samples have often been based on clinical convenience 
rather than on epidemiological principles, involving small sample sizes, and recruiting from specific 
settings and locations (Carrà and Johnson, 2009). In addition, the assessment of substance use has 
often been inadequate, with relatively few studies making full diagnostic assessments (Drake et al., 
1993). Moreover, correlates have been described in relation, variously, to point, period and life-time 
prevalence (Goldfinger et al., 1996), and dependence disorders involving alcohol and other drugs 
have frequently not been distinguished from DSM-IV abuse (ICD–10 harmful use), though the 
consequences of dependence may be much more severe than those of harmful use in people with 
schizophrenia (Olfson et al., 2002; Potvin et al., 2006a; Kerfoot et al., 2011; Carrà et al., 2015). 
Indeed, DSM 5 has combined DSM-IV substance abuse and dependence into a single disorder, 
measured on a mild to severe continuum of severity (Hasin et al., 2013; Bartoli et al., 2015). 
Though the bulk of the evidence is from the US, a significant body of research has now built up in 
Europe (i.e., Soyka et al., 2001; van Os et al., 2002;  Weaver et al., 2003; Morrens et al., 2011). 
This has contributed to the development of specialized treatment programs for these complex 
clinical populations, whose models of comorbidity are not entirely clear (Carretta et al., 2015). 
The characteristics of clinical populations with both schizophrenia and substance use disorders are 
universally worse than their non-abusing counterparts (Margolese et al., 2004; Kerner, 2015), 
including clinical (Kerfoot et al., 2011; Jones et al., 2011), physical (Rosenberg et al., 2001) and 
legal (Carrà et al., 2015) outcomes. Nonetheless, it has been suggested that psychosocial 
functioning and quality of life (QoL) might actually be better in substance-abusing people with 
schizophrenia than in those who are abstinent, given that they need the skills to engage with drug-
dealers in order to secure supplies (Salyers and Mueser, 2001; Swartz et al., 2006b). However, this 
might only be true in those people with schizophrenia who misuse drugs and alcohol rather than 
those with actual dependence. The issue has been clouded, both by the question of cross-cultural 
applicability (Heinrichs et al., 1984), and by problems in content validity (Schooler et al., 1979). 
Finally, since the correlates of dependence on alcohol in the general population differ from those of 
dependence on other drugs (Rehm et al., 2006), this may also be the case in people with 
schizophrenia.  
More precise knowledge of the correlates of comorbid substance misuse should increase 
understanding of the impact of local social circumstances on these associations, and the 
identification of clinical subpopulations with residual competencies and skills, suitable for targeting 
with specialist treatment programmes (Carrà et al., 2006).  
The European Schizophrenia Cohort (EuroSC) survey provides an opportunity to do this, as it was 
specifically set up to compare the attributes and correlates of schizophrenia in three European 
countries, France, Germany and the UK (Bebbington et al., 2005). Using a large and representative 
sample of people with schizophrenia in community mental health care, it showed lifetime rates of 
35% for comorbid dependence on any substance in the UK, but considerably lower values in 
Germany (21%) and in France (19%). These differences between countries persisted after 
controlling for individual clinical and demographic characteristics (Carrà et al., 2012).  
Our aim in the current study was to use the baseline EuroSC data to investigate cross-nationally the 
socio-demographic, clinical, social functioning and quality of life (QoL) correlates of dual diagnosis 
in people with schizophrenia. We examined dependence on alcohol and on other drugs separately. 
We hypothesised that, after adjusting for country of residence, people with schizophrenia and 
comorbid dependence would have significantly worse clinical symptoms, psychosocial functioning, 
and quality of life. As a secondary hypothesis, we predicted that drugs would be associated with 
fewer impairments in psychosocial functioning and QoL than dependence on alcohol. 
 
 
2. Methods 
 
2.1 Sample 
The European Schizophrenia Cohort (EuroSC) survey was a naturalistic follow-up of a cohort of 
people aged 18 to 64, suffering from schizophrenia, and in contact with secondary psychiatric 
services, i.e., community outpatient services according to national organizational standards, in nine 
community mental health catchment areas in France, Germany, and the UK (Bebbington et al., 
2005). The current analysis is based on cross-sectional data from the first stage interview. Local 
ethical approval for the study was obtained in each country. The settings, sampling strategies and 
inclusion/exclusion criteria are fully described elsewhere (Bebbington et al., 2005). In brief, in 
France, people were recruited from three centres located in a city or in medium-size towns from 
northern (Lille), central (Lyon), and southern France (Marseille). In Germany four catchment areas 
were identified for the study: two in the former East Germany (Leipzig and the nearby Altenburg 
area) and two in the former West (Hemer and the County of Heilbronn). The British study centres 
were Islington, an inner-city area of London, and the reasonably affluent area of Leicestershire 
minus the city of Leicester. Random sampling from lists of service users was adopted in all the 
French centres and in London, while an exhaustive inclusion strategy was used for the German 
centres and Leicestershire. Eligible patients were aged 18–64 years at the time of enrolment in the 
study, had a diagnosis of schizophrenia according to DSM–IV criteria, and had given signed 
informed consent. People who had been hospitalised for the past 12 months, or were currently 
intoxicated, roofless or planning to leave the area, making follow-up assessment impracticable, 
were excluded. 
2.2 Procedure 
Individuals from the final list of participants were contacted consecutively by trained research 
assistants, seeking their informed consent, and fully reassuring them about their privacy protection 
also with the help of local clinicians if needed. If they agreed, they were interviewed at home or in a 
clinical facility over approximately three hours. Assessments sometimes required more than one 
session in order to avoid impairment of level of attention and willingness to collaborate. The study 
was observational, as no intervention was made either by, or at the behest of, the research team.  
2.3 Instruments 
An extensive battery of instruments was used to collect information during face to face interviews. 
Only those relevant to this paper are presented here. The Diagnostic interviews: SCAN - Schedules 
for Clinical Assessment in Neuropsychiatry - version 1.0 (WHO, 1992) was used to evaluate the 4-
week period before interview and the most significant period of earlier psychopathology. In the UK 
and Germany, SCAN was used with its component algorithm to establish diagnoses of 
schizophrenia. In the French centres, only the SCAN sections on alcohol and drug use were used, 
and the Structured Clinical Interview for DSM-IV (Spitzer et al., 1992) was used to identify 
schizophrenia. In all three countries, SCAN 1.0 algorithms were used to derive diagnoses of 
comorbid dependence on alcohol and on psychoactive substances other than alcohol. Information 
on current symptom profile was collected through the 30 item Positive and Negative Syndrome 
Scale (PANSS) (Norman et al., 1996), with positive, negative and general psychopathology 
symptoms sub-scores. The Quality of Life Interview (QoLI - Lehman, 1983) provided a global 
measure of life satisfaction, with a higher score indicating a better overall quality of life. The 
Calgary Depression Scale for Schizophrenia (CDSS) was used to measure depression (Addington et 
al., 1990, 1992). The Rating of Medication Influences (ROMI) Scale (Weiden et al., 1994) 
evaluated adherence to medication, with outputs scoring total “reasons for compliance” and 
“reasons for non-compliance”: higher scores signified, respectively, a greater willingness or 
reluctance, to take medication. The Clinical Global Impression (CGI) gives a single overall rating of 
the degree of mental illness on a 7-point scale (Busner and Targum, 2007). The Global Assessment 
of Functioning (GAF) provided an overall evaluation of functioning for people with psychiatric 
disorders, intentionally combining mental status and social function (APA, 1994). We also used the 
Global Assessment of Relational Functioning (GARF), which quantifies the relational context 
within which patients live and problems occur (Dausch et al., 1996), rating the degree to which the 
family (broadly defined) meets the affective and instrumental needs of its members in the areas of 
joint problem solving, organisation and emotional climate. Finally, the Extrapyramidal Rating Scale 
of Simpson and Angus (1970) was used to assess neuroleptic-induced Parkinsonism. 
2.4 Definitions of dual diagnosis 
We chose to focus on dependence rather than on harmful use of substances, because the latter is a 
residual diagnosis that cannot be made in people who meet criteria for dependence. Moreover, 
while the diagnosis of dependence, as defined in DSM–IV and ICD–10, has consistently been 
shown to be reliable and valid, reliability is far weaker for harmful use (abuse in DSM-IV) (Hasin 
et al., 2006). 
Our definitions of dual diagnosis were based on ICD-10 diagnoses of past year comorbid 
dependence due to the use of (1) alcohol, or (2) any psychoactive substance other than alcohol 
(F10-F16, F18-F19). We did not collect data about disorders due to the use of tobacco. 
Furthermore, because of high frequency of polysubstance dependence, dependence on specific 
substances of abuse could not be assessed. For brevity, in the text, tables and figures, we refer to 
alcohol dependence and drug dependence. In order to analyse mutually exclusive subgroups, people 
with both alcohol and drug dependence were assigned to the category of the most severe syndrome. 
2.5 Analysis 
Univariate analyses were carried out testing whether past year dependence syndromes on alcohol 
and on other drugs were associated with baseline characteristics by country. Univariate comparisons 
for categorical data were made between groups using Pearson’s chi-square test, and Student t and 
Mann-Whitney tests for continuous variables. In order to control for error effects, the Bonferroni 
multiple testing correction was used. 
Multivariate analyses were then used to test the association between different correlates and the two 
different, past year dependence syndromes, controlling for country. Multinomial logistic regression 
was used to identify a parsimonious subgroup of predictors among sociodemographic and clinical 
variables characterizing mutually exclusive groups of dependent people (i.e., individuals dependent 
on alcohol and on other drugs) in comparison with people without dependence. In order to identify 
the relevant correlates of the two dependence syndromes we followed a structured approach. For 
each psychosocial and clinical correlate, we fitted a multilevel mixed effects linear regression, 
modelling subject-level and country-level effects, and including identified predictors as covariates, 
in order to compare outcomes between the three groups (past year no dependence, dependence on 
alcohol, dependence on other drugs). Least square means for each predictor across groups were 
estimated, with p-values for joint tests. In addition, comparisons were conducted between pairs of 
groups, providing Bonferroni multiple testing corrections. Level of significance was set at 5%. 
Analyses were performed using the Stata statistical software package (version 13.0; StataCorp, 
College Station, Texas). 
 
3. Results 
In total, 1,204 people with schizophrenia participated in the study, 284 in France, 302 in the UK, 
and 618 in Germany. In general, participants had suffered from schizophrenia for a considerable 
period (13.5–16.6 years). There were minor but significant differences in the sociodemographic and 
clinical characteristics: nearly all varied significantly according to centre of residence. Further 
details are described elsewhere (Bebbington et al., 2005).  
3.1 Univariate group comparisons 
Paired comparisons showed significant differences between groups on 13 of 22 measures (Table 1). 
Generally, dependent participants were younger (significantly so for drug dependence), male, and 
single. Dependent participants living in France and Germany had a shorter duration of illness. 
Participants dependent on either alcohol or drugs had PANSS general psychopathology and positive 
subscale scores higher than those who were not dependent. Dependent individuals also had higher 
CDSS scores, poorer quality of life (QoL) scores, and worse scores on CGI, GAF, and GARF. 
There were no differences between groups in medication patterns and extrapyramidal rating scores.  
Multinomial logistic regression confirmed these independent differences between groups on the 
following measures: gender, family situation, living condition, age, ever worked, years of 
education, age of illness onset, length of illness, PANSS positive and negative, overall QoL, CGI, 
and GAF scores (all p<0.05; data available upon request). 
Insert Table 1 here 
3.2 Comparison of correlates 
Controlling for identified covariates, and incorporating both subject and country level effects, we 
used mixed models to compare outcomes between the drug dependent, alcohol dependent and non-
dependent groups. There were significant differences on the PANSS negative and general 
psychopathology subscales, and in quality of life (QoL), non-compliance with medication (ROMI), 
extrapyramidal side effects (EPS), and functioning on both the GAF and the GARF (Table 2). 
However, relative to the non-dependent group, people suffering from schizophrenia who were 
dependent on either alcohol or drugs had fewer symptoms on the PANSS negative subscale. 
Participants dependent on alcohol scored higher on the general psychopathology subscale than their 
drug-dependent and non-dependent counterparts. Compared to non-dependent participants, those 
dependent on drugs reported poorer quality of life, more extrapyramidal side effects, and poorer 
functioning on the GAF; people dependent on alcohol gave more reasons for non-compliance with 
medication, and reported poorer GAF functioning. However, there were no group differences on the 
GARF, which quantifies relational functioning in terms of problem solving, organisation and 
emotional climate.  
Insert Table 2 here 
 
4. Discussion 
We analysed a large international sample of people with schizophrenia, involving three 
European countries. ICD-10 and DSM-IV equivalent research diagnoses for schizophrenia 
and for comorbid dependence were based on formal diagnostic interviews. Taking into 
account country of residence, we were thus able to study psychosocial functioning, quality 
of life and the clinical correlates associated with concurrent past-year dependence on alcohol 
and other, illegal, substances. 
Our results show that people suffering from schizophrenia with comorbid dependence were more 
likely to be male, younger, and single, with shorter illnesses, more severe clinical symptoms, and 
poorer QoL and psychosocial functioning. People dependent on alcohol or on drugs had fewer 
symptoms on the PANSS negative subscale. On the general psychopathology subscale, participants 
dependent on alcohol scored higher than those dependent on drugs or with no dependence. Notably, 
there was no excess of PANSS positive symptoms in people suffering from schizophrenia with 
comorbid alcohol or drug dependence. Findings of fewer negative symptoms in comorbid substance 
users tally with the bulk of the literature (e.g., Swartz et al., 2006b; Kerfoot et al., 2011), which 
suggests a correspondence between the most severe dependence syndromes and attempts to 
alleviate dysphoria (e.g., Potvin et al., 2006a; Talamo et al., 2006). Nevertheless, fewer negative 
symptoms may reflect better premorbid functioning, in that drugs-using patients may have superior 
social skills in order to be able to acquire and sustain a drug habit (Salyers and Mueser, 2001). A 
rigorous assessment of comorbid dependence on alcohol or other drugs could thus help clinicians in 
order to anticipate typical clinical features which might orientate the choice of active components in 
treatment programs. These may include care in the community, assertive engagement, high 
intensity, small caseload, continuous responsibility and availability, consistent multidisciplinary 
team, a team approach, and cooperation with the patient’s support network (De Witte et al., 2014). 
In particular different levels of positive rather than negative psychotic symptoms on PANSS would 
also demand optimization of antipsychotic medication (Lingford-Hughes et al., 2012). However, 
only people suffering from schizophrenia who had comorbid alcohol dependence showed a 
significant impairment on the general psychopathology subscale, in which the items address general 
functional areas (e.g. cognitive, social, affective, and communicative). This is in line with findings 
linking alcohol dependence attributes such as craving with global psychiatric symptom severity 
(Batki et al., 2008). Along with the greater degree of EPS after controlling for medication status 
(Potvin et al., 2006b), it may also explain the associated medication non-compliance we found, 
consistent with previous research (Buckley, 2006).  
In contrast to many previous US samples (e.g., Swarz et al., 2006b; Talamo et al., 2006; Kerfoot et 
al., 2011), but consistent with some European studies (e.g., Dervaux et al., 2002), we did not find 
significantly higher PANSS-positive scores in our sample of schizophrenic subjects with comorbid 
dependence. However, more recent investigations from the USA, using latent class analysis based 
on the CATIE study (Tsai and Rosenheck, 2013) and the Molecular Genetics of Schizophrenia 
(MGS1) Collaboration study (Kerner, 2015) have also reported that comorbid substance use was 
unrelated to any specific pattern of positive symptoms. The findings in our study and in others 
might result from the relatively high level of positive symptoms consequent on the selection 
criteria, and may represent a floor effect. Our results do not entirely corroborate prior research in 
people with schizophrenia misusing substances indicating more social contacts and better social-
leisure functioning (possibly proxy measures of QoLI), albeit with coexistent more interpersonal 
and family problems (Salyers and Mueser, 2001) and higher overall psychosocial functioning 
(Swartz et al., 2006b). Indeed, regardless of country of residence, participants dependent on drugs 
or on alcohol had significantly lower QoL overall scores and poorer functioning on the GAF 
relative to their non-dependent counterparts. In contrast, there were no differences in relational 
functioning, as measured by the GARF. Thus our secondary hypothesis that people with 
schizophrenia and comorbid dependence (in particular those dependent on drugs) would have fewer 
impairments in psychosocial functioning and QoL was clearly refuted.  
It is possible that the degree of programming, organization, and social performance required for the 
acquisition of illicit drugs (Swartz et al., 2006b), may apply only to drug misuse, and not to drug 
dependence as analysed in our study.  
4.1 Limitations 
We acknowledge several limitations. First, we had no access to information on people who 
declined to participate in the study. While attempts were made to guarantee comparable 
recruitment procedures across the centres of the study, variations in the inpatient services 
available for addiction cannot be excluded. This could be controlled to an extent by 
controlling for country of study, but more specific differences in the availability of clinical 
resources might be included as potential confounding factors in future research. The 
procedure for identifying schizophrenia was based on the use of different standardised 
instruments (SCID and SCAN) that may identify different cases, although these are likely to 
be similar in their correlates (the identification of substance dependence was uniform across 
the three countries). The role of possible confounders has been addressed at the stage both of 
design (random sampling and exhaustive inclusion procedures) and of analysis (adjusting 
for a selected set of variables at subject-level and country-level). We did not cover special 
populations (e.g., prisoners, homeless, and those in residential long-term programmes) who 
may perhaps have more severe forms of substance disorders (Mojtabai, 2005), and we could 
not collect information about treatment in place for the dependence syndrome. In addition, 
because of idiosyncratic characteristics in the design and financing of European health 
services, our results may not generalize to other settings. Finally, limitations regarding 
temporal relationship and causality, inherent to cross-sectional design, should obviously be 
considered, and findings might not be the same in people out of contact with services. 
Future research should be planned in order to fill these gaps in this field of the scientific 
literature. 
 
4.2 Conclusions 
We have previously reported that in people with schizophrenia dependence on alcohol and 
other drugs is less frequent in Europe than in the USA (Carrà et al., 2012), though 
differential access to mental health systems might in part explain differences in prevalence 
rates (Carrà & Johnson, 2009). This study extends this research by suggesting that, at least 
across Europe, people with schizophrenia who are dependent on alcohol or drugs are more 
disabled than those who are not dependent. 
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